Fluvoxamine Maleate Rx
Generic Name and Formulations:
Fluvoxamine maleate 25mg, 50mg+, 100mg+; tabs; +scored.
Various generic manufacturers
Indications for Fluvoxamine Maleate:
≥18yrs: initially 50mg at bedtime, increase in 50mg increments at 4–7 day intervals; range 100–300mg/day; max 300mg/day. Divide total daily doses >100mg into 2 doses; give larger portion at bedtime. Elderly, hepatic impairment: use lower initial dose and titrate more slowly.
Females may respond to lower dose. <8yrs: not established. 8–17yrs: initially 25mg at bedtime, increase in 25mg increments at 4–7 day intervals; usual range 50–200mg/day. Max 8–11yrs: 200mg/day; 12–17yrs: 300mg/day. Divide total daily doses >50mg into 2 doses; give larger portion at bedtime. Hepatic impairment: use lower initial dose and titrate more slowly.
Concomitant alosetron, tizanidine, pimozide, thioridazine. During or within 14 days of MAOIs; do not start an MAOI during or within 14 days of fluvoxamine. Concomitant linezolid, IV methylene blue.
Suicidality and antidepressants.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults; monitor for clinical worsening or unusual changes. Screen for bipolar disorder. Monitor for serotonin syndrome; discontinue if occurs. History of seizures (discontinue if occurs), mania/hypomania. ECT. Cardiovascular disease. Liver dysfunction. Angle-closure glaucoma. Conditions that affect metabolism or hemodynamic response. Reduced activity of CYP2D6. Reevaluate periodically. Write ℞ for smallest practical amount. Avoid abrupt cessation. Elderly. Labor & delivery. Pregnancy (Cat.C); 3rd trimester: consider tapering dose. Nursing mothers: not recommended.
See Contraindications. Prolongation of QT interval with pimozide, thioridazine. Avoid alcohol. Concomitant ramelteon: not recommended. Increased risk of serotonin syndrome with other serotonergic drugs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, St. John's wort, linezolid, IV methylene blue; monitor. Potentiates diazepam (not recommended), triazolam and alprazolam (reduce their doses by at least ½), midazolam, theophylline (reduce its dose by ⅔ and monitor), warfarin, carbamazepine, tricyclic antidepressants (reduce their doses and monitor), propranolol, metoprolol (reduce their doses), clozapine, methadone, tacrine. Caution with drugs that inhibit CYP2D6 (eg, quinidine) or 3A4, phenytoin, diltiazem. Increased risk of bleeding with concomitant NSAIDs, aspirin, warfarin, and others that affect coagulation. Monitor mexiletine levels. Smokers may have increased metabolism.
Nausea, somnolence, insomnia, asthenia, nervousness, dyspepsia, abnormal ejaculation, sweating, anorexia, tremor, vomiting, anorgasmia, decreased libido, dry mouth, rhinitis, taste perversion, urinary frequency; hyponatremia (discontinue if symptomatic). Children: also agitation, depression, dysmenorrhea, flatulence, hyperkinesia, rash.
Formerly known under the brand name Luvox.
Clinical Pain Advisor Articles
- FDA Takes Steps to Reconcile Needs of Patients With Chronic Pain, Efforts to Curb Opioid Epidemic
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Stat Consult: Chronic Low Back Pain
- Opioid Misuse May Help Predict Alcohol Dependence Treatment Outcomes
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Predictors of Opioid Overdose in High-Risk Users
- FDA to Review Long-Acting Treatment for Opioid Use Disorder
- Half of Patients Referred for Behavioral Treatment of Migraine Never Initiate Treatment
- Low-Dose Sumatriptan Injection Effective as Acute Migraine Treatment
- The Fight for Patient Privacy Under Big Data Analytics